Methodology

All entries for: Takeda

May 15, 2026

Takeda

Layoffs

Tokyo
10,000+ employees

To cut back on costs, Takeda is rolling out a sweeping “transformation program” that will streamline corporate operations and see some 4,500 employees let go in fiscal year 2026, according to an earnings presentation. That number represents less than 10% of total roles globally and does not reflect hiring plans, a company spokesperson told BioSpace in an emailed response on May 13.

“Right now, we have 2,200 open roles globally and we expect to create new jobs throughout the year, which we are prioritizing filling with internal candidates,” the spokesperson said.

The layoffs will look different across the organization and will be phased according to unique business needs and country requirements, according to the spokesperson. They confirmed that the cuts include an estimated 247 roles in Massachusetts and 387 in other states outlined in a March Worker Adjustment and Retraining Notification (WARN) Act notice.

Disease Area: Dermatology, Immune Diseases, Multiple, Neurological Diseases, Oncology, Rare Diseases
Drug Type: Biologic, Small Molecule
Source
Source
March 31, 2026

Takeda

Layoffs

Tokyo
10,000+ employees

Takeda’s recently announced reorganization may affect approximately 634 U.S. employees, including 247 in Cambridge, Massachusetts effective July 1, 2026, through Dec. 31, 2027, and 387 in other states, though the total could change as staff pursue redeployment opportunities.

Disease Area: Multiple
Drug Type: Biologic, Small Molecule
Source
Source
March 26, 2026

Takeda

Layoffs

Tokyo
10,000+ employees

Takeda has announced a significant restructuring to streamline corporate functions and generate more than $1.25 billion in savings by fiscal year 2028, though the full workforce impact has not yet been disclosed.

Disease Area: Multiple
Drug Type: Biologic, Small Molecule
Source
Source
January 19, 2026

Takeda

Layoffs

Tokyo
10,000+ employees

Takeda is laying off 243 employees across its U.S. operations, an effort that will heavily affect its neuroscience commercialization teams.The spokesperson told the media outlet the workforce reduction was part of a “strategic decision” to help the company navigate its upcoming loss of exclusivity for Trintellix, a major depressive disorder drug. That decision also includes “reprioritizing resources to prepare for multiple potential new medication launches in the U.S.”

Disease Area: Multiple
Drug Type: Biologic, Small Molecule
Source
Source
October 3, 2025

Takeda

Layoffs

Tokyo
10,000+ employees

Takeda is laying off 137 employees. According to an Oct. 1 Worker Adjustment and Retraining Notification (WARN) Act notice, those staffers, located in Cambridge, Massachusetts, are being let go effective Jan. 1 through July 31, 2026.

Disease Area: Multiple
Drug Type: Biologic, Small Molecule
Source
Source
February 5, 2025

Takeda - Cambridge

Discontinued Research

Cambridge, MA
10,000+ employees

The clinical trial titled “A Study of TAK-951 in Participants With Cyclic Vomiting Syndrome (CVS)” (NCT06768658), sponsored by Takeda, was terminated due to business reasons before enrolling any participants. Specific details regarding these business reasons were not disclosed.

1 Discontinued Research Program

Disease Area: Chronic Disease
Drug Type: Small Molecule
Source
Source
October 21, 2024

Takeda

Layoffs

Tokyo
10,000+ employees

“Takeda is laying off dozens of employees in Massachusetts, according to a Worker Adjustment and Retraining Notification (WARN) alert filed with the state late last week. The layoff process kicked off in late September and will run through March of next year, according to state records.

“While the WARN alert states that 79 employees across the two sites are set to face cuts, the final number “is not clear at this time” and will depend on potential “redeployment opportunities,” according to a detailed filing cited by Boston Business Journal.”

Disease Area: Multiple
Drug Type: Biologic, Small Molecule
Source
Source
March 31, 2024

Takeda

Negative Outlook

Tokyo
10,000+ employees

“We expect the IRA to negatively impact sales and profits and may lead to further political pressure, or legislative, regulatory, or other efforts to introduce lower prices reduce spending on the Medicare and Medicaid programs expand and strengthen the affordable care act and lower, the overall spending by the government and prescription medicines. In addition, various state legislature and regulators have an acted or pursuing policy changes that could further increase pricing pressure on our products as a result we expect the healthcare industry in the US will continue to be subject to increase pricing and spending pressure.”

Disease Area: Multiple
Drug Type: Biologic, Small Molecule
Source
Source
Scroll to Top